title: High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patients.
abstract: The main objective of this study was to determine whether elevated blood beta-amyloid (Abeta) levels among the first-degree relatives of patients with Alzheimer's Disease (AD) are associated with vascular risk factors of AD. Serum Abeta was measured in samples from 197 cognitively normal first-degree relatives of patients with AD-like dementia. Study participants were recruited as part of an ancillary study of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT subpopulation). The ADAPT subpopulation was found to be similar in age, sex, and ethnicity to another cognitively normal cohort (n = 98). Using cross-sectional analyses, we examined the association of Abeta with blood pressure, lipid levels, apolipoprotein E genotypes, and the use of prescribed medication to treat vascular risk factors in the ADAPT subpopulation. Abeta(1-40) was positively associated with age, use of antihypertensives, and serum creatinine, and we observed a marginal negative interaction on Abeta(1-40) associated with systolic blood pressure and use of antihypertensives. Serum Abeta(1-42) was associated with statin use and a positive correlation of Abeta (1-42) with HDL was observed among statin nonusers. These findings suggest that high Abeta in the periphery among the family history-enriched cohorts may be due to enrichment of vascular risk factors and may reflect presymptomatic AD pathology. It remains to be determined whether the association of Abeta with medications used for treating vascular risk factors indicates prevention of AD. Longitudinal evaluation of blood Abeta in this cohort will provide a better understanding of the significance of this association in AD etiology.
authors.affiliation: Roskamp Institute, Sarasota, Florida 34243, USA. labdullah@rfdn.org
authors.forename: Laila
authors.initials: L
authors.lastname: Abdullah
authors.forename: Cheryl
authors.initials: C
authors.lastname: Luis
authors.forename: Daniel
authors.initials: D
authors.lastname: Paris
authors.forename: Ghania
authors.initials: G
authors.lastname: Ait-ghezala
authors.forename: Benoit
authors.initials: B
authors.lastname: Mouzon
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Allen
authors.forename: Julia
authors.initials: J
authors.lastname: Parrish
authors.forename: Myles A
authors.initials: MA
authors.lastname: Mullan
authors.forename: Scott
authors.initials: S
authors.lastname: Ferguson
authors.forename: Marcie
authors.initials: M
authors.lastname: Wood
authors.forename: Fiona
authors.initials: F
authors.lastname: Crawford
authors.forename: Michael
authors.initials: M
authors.lastname: Mullan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood* / Q000473:pathology* / Q000517:prevention & control; D016229:Amyloid beta-Peptides / Q000097:blood*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001808:Blood Vessels / Q000378:metabolism / Q000473:pathology*; D005190:Family; D005260:Female; D006801:Humans; D010446:Peptide Fragments / Q000097:blood*; D012307:Risk Factors
chemical_list: D016229:Amyloid beta-Peptides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)